Bruker Co. (NASDAQ:BRKR) Shares Purchased by Fmr LLC

FMR LLC lifted its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 21.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 14,306,122 shares of the medical research company's stock after buying an additional 2,521,904 shares during the period. FMR LLC owned 9.44% of Bruker worth $987,981,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of BRKR. The Manufacturers Life Insurance Company increased its stake in Bruker by 3.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 115,616 shares of the medical research company's stock worth $7,984,000 after buying an additional 4,247 shares during the period. Bank of Montreal Can boosted its stake in Bruker by 31.2% during the 3rd quarter. Bank of Montreal Can now owns 61,138 shares of the medical research company's stock valued at $4,321,000 after purchasing an additional 14,547 shares during the period. Brown Brothers Harriman & Co. lifted its stake in shares of Bruker by 39.9% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 602,144 shares of the medical research company's stock worth $41,584,000 after acquiring an additional 171,806 shares during the period. Daiwa Securities Group Inc. bought a new stake in shares of Bruker in the 3rd quarter worth approximately $435,000. Finally, Algert Global LLC raised its holdings in shares of Bruker by 62.9% in the 3rd quarter. Algert Global LLC now owns 163,926 shares of the medical research company's stock worth $11,321,000 after purchasing an additional 63,296 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Stock Performance

Shares of NASDAQ BRKR traded up $0.88 during midday trading on Thursday, hitting $58.38. 1,436,451 shares of the company's stock traded hands, compared to its average volume of 1,115,677. The firm has a fifty day moving average of $61.02 and a 200 day moving average of $64.24. The stock has a market capitalization of $8.85 billion, a price-to-earnings ratio of 28.07, a price-to-earnings-growth ratio of 3.95 and a beta of 1.20. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to analysts' expectations of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. Bruker's revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.74 EPS. On average, analysts forecast that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date is Monday, December 2nd. Bruker's payout ratio is currently 9.62%.

Insiders Place Their Bets

In other news, CEO Frank H. Laukien acquired 100,000 shares of the company's stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the purchase, the chief executive officer now directly owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 28.30% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BRKR. Wolfe Research lowered shares of Bruker from an "outperform" rating to a "peer perform" rating in a research note on Monday, September 30th. TD Cowen dropped their price objective on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research note on Wednesday, November 6th. Barclays dropped their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company decreased their price objective on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th. Finally, Citigroup reduced their target price on shares of Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.